Biotech company Neurotech Pharmaceuticals this month received regulatory approval for its treatment of a a neurodegenerative ...
This milestone marks a significant step forward in Rakovina’s mission to accelerate drug discovery using advanced AI-driven platforms. In September 2024, Rakovina announced its partnership with ...
The US Food and Drug Administration (FDA) has approved Encelto (revakinagene taroretcel-lwey) for the treatment of macular ...
Symptom severity, meibum quality, and telangiectasia are factors affecting prognostic outcomes for intense pulsed light therapy.
Insights shed light on what the approval means for providers and their patients affected by this neurodegenerative retinal ...
The US Food and Drug Administration (FDA) has approved the biologics license application (BLA) for Encelto (revakinagene ...
MyChesCo on MSN7d
FDA Approves Breakthrough Eye Therapy and Expands Life-Saving Allergy Spray for KidsThe U.S. Food and Drug Administration (FDA) has announced significant advancements in medical treatments, including the ...
The FDA approved revakinagene taroretcel (Encelto) as the first treatment for adults with idiopathic macular telangiectasia ...
Neurotech Pharma's cell therapy Encelto has become the first FDA-approved treatment for idiopathic macular telangiectasia ...
The first treatment for macular telangiectasia type 2 is set to enter the market following U.S. FDA approval of NT-501 ...
MacTel is a rare, progressive eye disease that affects the macula and causes a gradual deterioration in central vision.
Phase 3 trials demonstrated ENCELTO significantly slowed macular photoreceptor loss in MacTel patients over 24 months.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback